Novartis AG (XSWX:NOVNEE) DeferredTaxAndRevenue: CHF0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:NOVNEE Novartis AG XSWX:NOVNEE
80 GF Score
Price CHF119.30
GF Value CHF98.85
! 7 Warning Signs
View Full Analysis

What is Novartis AG DeferredTaxAndRevenue?

Novartis AG XSWX:NOVNEE -0.52% 80 DeferredTaxAndRevenue is CHF0 Mil as of Mar. 2026. GuruFocus rates XSWX:NOVNEE with a GF Score™ of 80/100 and a GF Value™ of CHF98.85. The stock has 7 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Novartis AG's current deferred tax and revenue for the quarter that ended in Mar. 2026 was CHF0 Mil.

Novartis AG DeferredTaxAndRevenue Related Terms

Novartis AG DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Novartis AG's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG DeferredTaxAndRevenue Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 113.28 114.59 84.75 0.00 0.00

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:NOVNEE
80GF Score
Novartis AG XSWX:NOVNEE
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of CHF0 Mil mean?
Novartis AG (XSWX:NOVNEE) has a DeferredTaxAndRevenue of CHF0 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Novartis AG.
Is Novartis AG's DeferredTaxAndRevenue too high?
Novartis AG's current DeferredTaxAndRevenue is CHF0 Mil. Overall, Novartis AG has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's DeferredTaxAndRevenue compare to LLY and JNJ?
Novartis AG's DeferredTaxAndRevenue of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Drug Manufacturers company?
A good DeferredTaxAndRevenue depends on the Drug Manufacturers industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Novartis AG. Novartis AG's current DeferredTaxAndRevenue is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Novartis AG (XSWX:NOVNEE) has a current DeferredTaxAndRevenue of CHF0 Mil. The stock's GF Value™ is CHF98.85, compared to a current price of CHF119.30 — trading 20.7% above its estimated fair value. The current DeferredTaxAndRevenue is CHF0 Mil. Novartis AG's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Novartis AG (XSWX:NOVNEE), the current DeferredTaxAndRevenue is CHF0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (XSWX:NOVNEE) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of CHF119.30 is trading 20.7% above its estimated GF Value™ of CHF98.85.

Key valuation signals for XSWX:NOVNEE:

  • DeferredTaxAndRevenue: CHF0 Mil
  • GF Value™: CHF98.85 vs. price of CHF119.30 (20.7% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the XSWX:NOVNEE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
80GF Score

Get the complete analysis for XSWX:NOVNEE

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF119.30
Price
CHF98.85
GF Value